Research area · week to 3 Oct 2026

Inhalation and Respiratory Drug Delivery

Moving in bioRxiv, BMJ, Environmental pollution, Environmental research, Nature Communications, Nature Microbiology.

Moved this week: 0

Rebuilt 3 October 2026 at 5:53 pm AEST

Moved this week

Everything that moved →

Nothing in this area has moved yet this week.

Latest in Inhalation and Respiratory Drug Delivery

Newest first · last 60 days

Short-term effects of PM(10) sources and oxidative potential on child lung function.
Environmental pollution · 15 Sept 2026 · Journal Article
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42309251
Open in JClub
Multi-modal microRNA and non-targeted proteome analysis of liquid biopsies from the distal lung collected by Particles in Exhaled Air (PExA) reveal presence from extracellular vesicles
bioRxiv · 7 Sept 2026 · Preprint
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2024.11.12.620657
Open in JClub
Acute controlled wood smoke exposure induces sensory airway irritation without detectable changes in small airway mechanics in healthy adults: A randomized crossover study.
Environmental research · 7 Sept 2026 · Randomized Controlled Trial
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42705439
Open in JClub
Survival of the driest.
Nature Microbiology · 31 Aug 2026 · Journal Article
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42675205
Open in JClub
Zinc displacement and metabolic interference: cobalt ion-mediated therapy for broad-spectrum CRKP-resistant pneumonia via inhalable microspheres.
Nature Communications · 12 Aug 2026 · Journal Article
Read the brief in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42717206
Open in JClub
Comparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial.
BMJ · 5 Aug 2026 · Comparative Study
Azithromycin reduces the risk of moderate or severe COPD exacerbations by 17% compared to roflumilast in routine clinical practice among patients over 40.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42556860
Open in JClub

Follow this area in the app

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read

Moved this week

Latest in Inhalation and Respiratory Drug Delivery

Short-term effects of PM(10) sources and oxidative potential on child lung function.

Multi-modal microRNA and non-targeted proteome analysis of liquid biopsies from the distal lung collected by Particles in Exhaled Air (PExA) reveal presence from extracellular vesicles

Acute controlled wood smoke exposure induces sensory airway irritation without detectable changes in small airway mechanics in healthy adults: A randomized crossover study.

Survival of the driest.

Zinc displacement and metabolic interference: cobalt ion-mediated therapy for broad-spectrum CRKP-resistant pneumonia via inhalable microspheres.

Comparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial.

Browse JClub